Literature DB >> 9029102

Polymorphism in the alpha 1 helix of the HLA-B heavy chain can have an overriding influence on peptide-binding specificity.

L D Barber1, L Percival, K L Arnett, J E Gumperz, L Chen, P Parham.   

Abstract

Previously, we reported overlap in the repertoires of peptides endogenously bound by a group of HLA-B allotypes related to HLA-B7. Extending such analysis to four members of the B17 family and seven members of the B15 family shows that allotypes that share sequence identity in the alpha 1 helix of the class I heavy chain possess markedly similar peptide-binding specificities. Members of the B17 family share a preference for peptides with serine, threonine, or alanine at position 2 and aromatic residues at the carboxyl terminus. Strikingly, the presence of a segment of the B17 alpha 1 helix in B*1516 and B*1517 confers the B17-like peptide-binding motif. The strong influence of natural variation in the alpha 1 helix is exemplified by the differences in peptide-binding specificity of B15 allotypes related by conversion events that replaced segments of the alpha 1 helix. In contrast, evolutionary changes that are confined to the alpha 2 domain confer less dramatic change. They do not perturb the primary anchors of the peptide-binding motif but can modulate the specificity through development and diversification of secondary anchors. Our results, in combination with those obtained previously for other HLA-B allotypes, suggest a general trend whereby polymorphism in the alpha 1 helix is the overriding influence on peptide-binding specificity of HLA-B allotypes, while amino acid substitutions in the alpha 2 domain play a more modulatory role.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9029102

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other.

Authors:  P J Goulder; Y Tang; S I Pelton; B D Walker
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Mechanisms involved in the Abacavir-mediated hypersensitivity syndrome.

Authors:  Anuska Llano; Christian Brander
Journal:  Cell Res       Date:  2012-07-10       Impact factor: 25.617

Review 3.  Innate immune control of HIV.

Authors:  Mary Carrington; Galit Alter
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

4.  Immune self-reactivity triggered by drug-modified HLA-peptide repertoire.

Authors:  Patricia T Illing; Julian P Vivian; Nadine L Dudek; Lyudmila Kostenko; Zhenjun Chen; Mandvi Bharadwaj; John J Miles; Lars Kjer-Nielsen; Stephanie Gras; Nicholas A Williamson; Scott R Burrows; Anthony W Purcell; Jamie Rossjohn; James McCluskey
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

5.  Human leukocyte antigen B58 supertype and human immunodeficiency virus type 1 infection in native Africans.

Authors:  Aleksandr Lazaryan; Elena Lobashevsky; Joseph Mulenga; Etienne Karita; Susan Allen; Jianming Tang; Richard A Kaslow
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity.

Authors:  Michael A Norcross; Shen Luo; Li Lu; Michael T Boyne; Mary Gomarteli; Aaron D Rennels; Janet Woodcock; David H Margulies; Curtis McMurtrey; Stephen Vernon; William H Hildebrand; Rico Buchli
Journal:  AIDS       Date:  2012-07-17       Impact factor: 4.177

Review 7.  NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection.

Authors:  G Alter; M Altfeld
Journal:  J Intern Med       Date:  2009-01       Impact factor: 8.989

8.  Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A.

Authors:  Mark A Brockman; Arne Schneidewind; Matthew Lahaie; Aaron Schmidt; Toshiyuki Miura; Ivna Desouza; Faina Ryvkin; Cynthia A Derdeyn; Susan Allen; Eric Hunter; Joseph Mulenga; Paul A Goepfert; Bruce D Walker; Todd M Allen
Journal:  J Virol       Date:  2007-08-29       Impact factor: 5.103

9.  The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences.

Authors:  Stephen A Migueles; Alisha C Laborico; Hiromi Imamichi; W Lesley Shupert; Cassandra Royce; Mary McLaughlin; Linda Ehler; Julia Metcalf; Shuying Liu; Claire W Hallahan; Mark Connors
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients.

Authors:  Hayley Crawford; Wendy Lumm; Alasdair Leslie; Malinda Schaefer; Debrah Boeras; Julia G Prado; Jianming Tang; Paul Farmer; Thumbi Ndung'u; Shabir Lakhi; Jill Gilmour; Paul Goepfert; Bruce D Walker; Richard Kaslow; Joseph Mulenga; Susan Allen; Philip J R Goulder; Eric Hunter
Journal:  J Exp Med       Date:  2009-03-23       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.